Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vitrakvi | larotrectinib | Solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
Vitrakvi | Larotrectinib | NTRKplus solid tumours | Do not reimburse | Complete | ||
Vizimpro | Dacomitinib | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Vocabria and Cabenuva | cabotegravir sodium cabotegravir-rilpivirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete | ||
Vonvendi | von Willebrand Factor [recombinant] | von Willebrand disease, adults, treatment and perioperative management | Reimburse with clinical criteria and/or conditions | Complete | ||
Vosevi | sofosbuvir velpatasvir voxilaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
Votrient | Pazopanib Hydrochloride | Soft Tissue Sarcoma | Do not reimburse | Complete |